ANI Pharmaceuticals, Inc. (ANIP) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

76OpportunityDD: Jun 10, 2026Analyst: 79

paidPrice at analysis date

USD 80.3 (10/06/2026)

domainMkt cap

$1.78B

pie_chartShares

22.75M

candlestick_chart52W

$56.71-$99.50

trending_downShort interest

15.76%

INFONASDAQHealth Care970 employeesFounded 2001

Verdict: Favorable Risk/Reward —

Profitable specialty pharma with Q1 2026 beat (+20.5% revenue, EPS doubled), Rare Disease franchise (Cortrophin Gel +42% to $75M/qtr) driving multi-year growth, fresh $100M buyback, and raised guidance to $1.08-1.14B. Forward P/E 8.5-9x stands materially below growth-adjusted peer median. Key offsets: 15.76% short interest, $625M debt load (including converts), Cortrophin concentration.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-10

ANI Pharmaceuticals (ANIP)

Specialty & Generic Pharma · NASDAQ · Princeton, NJ

"Profitable rare-disease specialty pharma, beat-and-raise, trading at growth-adjusted discount."

Q1 2026 beat-and-raise $100M buyback active Forward P/E ~8.5x Cortrophin concentration Short interest 15.8% Net leverage 1.3x

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — Sum-of-the-Parts (Segment EV/Revenue) + EV/EBITDA cross-check

Fair value base case

USD 105.0

Range: USD 90.0-USD 122.0

Price at analysis date: USD 80.3 (10/06/2026)

Base upside/downside: +31%

Methodology: Segment-level SotP applied to FY26E guidance midpoint. Multiples derived from peer median (AMPH 6.24x, INVA 6.45x EV/EBITDA TTM) with growth premium for Rare Disease (+20.5% revenue, +24% adj EBITDA YoY) and Cortrophin's status as the only FDA-approved ACTH therapy. Implied EV/EBITDA 8.5x is +35% vs peer median, justified numerically by 2x peer growth rate. Cross-check at 8x EV/EBITDA confirms range within ±8%. ⚠️ Not investment advice.

Component	Assumption	USD/share
Rare Disease segment EV	$640M FY26E rev (Cortrophin $557M + ILUVIEN $80M mid-guide) × 3.0x EV/Rev → $1,920M / 22.0M shares	+87.3
Generics segment EV	$420M FY26E rev (run-rate +5%) × 1.0x EV/Rev → $420M / 22.0M shares	+19.1
Brand royalties EV (Harmony etc.)	~$50M FY26E rev × 4.0x EV/Rev → $200M / 22.0M shares	+9.1
Net debt	($311M cash − $625M total debt) / 22.0M shares	−14.3
Buyback NPV (announced)	$100M program × 60% probability of full execution / 22.0M shares	+2.7
FV base case	Sum of components above	≈ $104

Bull

$120–135

Probability: 25%

Cortrophin hits high end of guide ($575M), gout indication launches on schedule and ramps faster, Q3 SYNCHRONICITY trial positive, buyback executed aggressively, re-rating to 9-10x EV/EBITDA on Rare Disease premium.

Base

$95–115

Probability: 50%

Execution on FY26 guidance midpoint ($1.11B revenue), gout ramps gradually, modest re-rating to 8-8.5x EV/EBITDA, buyback supports float, Cortrophin durability intact through 2027.

Bear

$58–72

Probability: 25%

Cortrophin growth decelerates as ACTH penetration approaches saturation, payer pushback on pricing, generics margin compression, multiple compression to 6-7x EV/EBITDA in line with stagnant peers.

Methodology: Methodology: Segment-level SotP applied to FY26E guidance midpoint. Multiples derived from peer median (AMPH 6.24x, INVA 6.45x EV/EBITDA TTM) with growth premium for Rare Disease (+20.5% revenue, +24% adj EBITDA YoY) and Cortrophin's status as the only FDA-approved ACTH therapy. Implied EV/EBITDA 8.5x is +35% vs peer median, justified numerically by 2x peer growth rate. Cross-check at 8x EV/EBITDA confirms range within ±8%. ⚠️ Not investment advice. Not investment advice.

check_circle

✅ Recent Catalyst — Q1 2026 beat + raised guidance + $100M buyback (May 8, 2026)

Q1 2026: revenue $237.5M (+20.5% YoY, +14% vs consensus, largest beat among 17 tracked pharma stocks); net income $29.5M vs $15.7M PY; adj non-GAAP EPS $2.05; adj EBITDA +24% YoY. Management raised FY26 revenue guidance to $1.08-1.14B (from prior ~$1.04B implied), Cortrophin to $540-575M, ILUVIEN to $78-83M. Board authorized $100M buyback through May 2029. Combined signal: confident execution + capital return + value posture.

📊 Capital Structure · Short Interest · Buyback & Dilution

🔴 Short Interest

15.76%

3.58M shares shorted on 22.75M outstanding. High level — squeeze potential exists but reflects bearish thesis on Cortrophin durability + debt concerns.

🟡 Share dilution (1Y)

+3.0%

From ~22.1M to 22.75M shares. Modest organic dilution from equity comp + convertible-note overhang ($625M total debt incl. convertibles).

🟢 Buyback

$100M

New 3-year program authorized May 8, 2026 (through May 2029). Open market + 10b5-1 + private transactions. ~5.5% of market cap.

Short Interest — context

ANIP — 15.76%

15.76%

Short interest of 15.8% sits in the "high" band (15-25%). The bearish thesis appears to be: (i) Cortrophin's growth rate is unsustainable as ACTH is a niche segment, (ii) $625M debt load including convertibles creates structural dilution overhang, (iii) NEW DAY trial primary endpoint miss casts doubt on ILUVIEN expansion. Counter-positives: ongoing beat-and-raise, fresh buyback, net leverage only 1.3x. Combined: a Cortrophin guide raise in Q2 2026 earnings could trigger short-squeeze dynamics.

Insider transactions: Most recent disclosed Form 4: SVP & General Counsel Meredith W. Cook sold 400 shares at $90.09 in October 2025 under Rule 10b5-1 plan — routine, immaterial ($36K). No large insider sales (>$500K) found in the 12-month window. No class action, SEC investigation, or short-seller report identified.

$Financial analysis — FY 2025 + Q1 2026 + Guidance FY 2026

Revenue (TTM)

$883M

+43.8% YoY · raised guide $1.08-1.14B FY26

Adj EBITDA FY26E

~$305M

+24% YoY Q1 · ~27% margin

Net Cash / Debt

−$314M

Cash $311M · Debt $625M · Leverage 1.3x

Forward P/E

~8.5x

Below S&P 500 / peer median · value posture

Item	FY2023	FY2024	FY2025	Q1 2026	Guidance FY2026
Revenue ($M)	485	614	863	237.5	1,080 – 1,140
Cortrophin Gel ($M)	117	198	347.8	75.1	540 – 575
ILUVIEN ($M)	—	~50	~70	19.3	78 – 83
Generics ($M)	275	310	~395	105.4	~415 – 430
Adj EBITDA ($M)	108	175	~225	~62	~290 – 320
Adj non-GAAP EPS ($)	3.51	5.43	~7.95	2.05	9.19 – 9.69
Operating cash flow ($M)	52	110	~190	58.4	~$220+

Note: FY23-24 figures consolidated from press releases. Q1 2026 metrics are reported (Form 8-K May 8, 2026). FY26E guidance midpoint adopted: revenue $1.11B, EPS $9.44, EBITDA estimated from historical margin expansion.

Quarterly dynamics — last 5 quarters
Metric	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Revenue ($M)	197.1	205.4	227.8	232.3	237.5
Cortrophin Gel ($M)	52.8	71.3	101.9	121.8	75.1
Adj EBITDA margin %	23%	25%	27%	27%	26%
Net income ($M)	15.7	18.4	23.2	21.5	29.5
Cash EOP ($M)	240	265	290	305	311

Financial position and sustainability

Net leverage (Net debt / FY26E EBITDA)

1.03x

Cortrophin concentration (% total revenue)

~50%

Forward P/E vs peer median

−30% vs AMPH

Adj EBITDA YoY growth (Q1 2026)

+24%

account_tree

Business model — Specialty + Rare Disease + Generics platform

Three-segment specialty pharma with rare-disease growth engine

ANI is a Princeton-NJ biopharma operating across (1) Rare Disease — anchored by Purified Cortrophin Gel (ACTH therapy, only FDA-approved option in acute gouty arthritis flares + autoimmune indications) and ILUVIEN (intravitreal implant for diabetic macular edema and non-infectious posterior uveitis), (2) Generics — injectables, oral solids, semi-solids, liquids, controlled substances, and (3) Brands + royalties (including Harmony royalty stream). The Rare Disease segment is the strategic core: ~60% of FY26 revenue at superior gross margins; Cortrophin in particular is showing 40%+ growth driven by expansion in gout flares (now >15% of Cortrophin Rx) and the new prefilled-syringe form approved March 2025.

Rare Disease (Cortrophin + ILUVIEN) ~$620-660M FY26E (~58% rev) 🟢 ramping Cortrophin Gel: only FDA-approved ACTH therapy, +42% QoQ growth, gout expansion underway (~90-person sales force expansion mid-2026). ILUVIEN: intravitreal implant for DME/NIU-PS, +19.5% YoY. High-GM (60-65%+) franchise. Generics ~$415-430M FY26E (~38% rev) 🟡 stable Injectables, softgel capsules, controlled substances, oral solids/semi-solids/liquids. Q1 2026 +6.8% YoY. Lower-margin commodity exposure but stable revenue baseline; serves wholesalers, specialty pharmacies, retail chains. Brands + Royalties ~$45-55M FY26E (~4% rev) 🔴 declining branded Branded revenue −50.9% Q1 2026 on demand normalization. Offset: Brand royalties Q1 includes $15M Harmony upfront + ~$6.5M royalties. Low-volume, high-incremental-margin segment.

gavel

Legal, regulatory and risk analysis

Cortrophin concentration risk

High

Cortrophin Gel represents ~50% of total FY26 revenue. Any payer pushback, manufacturing disruption, or unexpected competitive entry (no direct ACTH competitor today, but biosimilar pathways possible) would have outsized impact on the thesis and multiple.

Debt + convertible overhang

Moderate

$625M total debt principal includes senior convertible notes — structural dilution risk if share price rallies through conversion strikes. Net leverage 1.3x is manageable; refinancing schedule must be monitored.

High short interest

Moderate

15.76% short interest (3.58M shares) signals meaningful bearish positioning. Two-edged: (i) downside catalyst if Cortrophin growth disappoints, (ii) upside squeeze potential on a beat-and-raise Q2 2026 print.

NEW DAY primary endpoint miss

Moderate

NEW DAY trial of ILUVIEN in DME missed primary endpoint (2.4 vs 2.5 supplemental aflibercept injections, p=0.756). Secondary endpoint (time between treatments) was significantly positive. Limits ILUVIEN expansion narrative; ophtho franchise growth becomes more incremental than transformational.

Drug pricing / payer policy

Moderate

US specialty pharma faces ongoing pressure from Medicare drug negotiation (IRA), PBM rebate compression, prior-authorization expansion. Cortrophin's premium ACTH pricing is a target — though no specific challenge currently disclosed.

Profitability + cash generation

Positive

Q1 2026 operating cash flow $58.4M; FY26E ~$220M+. Cash position $311M plus credit facilities. Buyback authorization signals durable FCF profile vs growth-phase peers burning cash.

Beat-and-raise execution track record

Positive

Multi-quarter pattern of revenue beats vs consensus (+14% Q1 2026, largest among 17 tracked pharma names) and management raising guidance each cycle. Lalwani's CEO tenure since 2021 has executed cleanly on Cortrophin commercialization.

No active litigation / compliance issues

Positive

No class action, SEC investigation, short-seller report, or material insider selling (>$500K) identified in trailing 12 months. Routine 10b5-1 transactions only. Clean governance profile.

article

SWOT analysis

Strengths

+Only FDA-approved ACTH therapy (Cortrophin) — true regulatory moat in gout flares + autoimmune indications
+Beat-and-raise execution: Q1 2026 revenue +20.5% YoY, EPS doubled, guidance raised mid-cycle
+Strong FCF profile — Q1 OCF $58.4M, $311M cash, $100M buyback active
+Forward P/E ~8.5x vs sector/peer median ~12x: value posture for a growth company
+Multi-segment diversification limits single-product risk vs pure-play biotech

Weaknesses

−Cortrophin concentration: ~50% of revenue from a single ACTH franchise
−$625M total debt incl. convertibles — refinancing + dilution risk to monitor
−NEW DAY trial primary endpoint missed — caps ILUVIEN bull case
−Branded revenue −50.9% Q1 — secular decline in this segment
−Mid-cap specialty pharma — limited analyst coverage (12 analysts) vs large pharma

Opportunities

→Gout flare indication launch (mid-2026, 90-person sales expansion) — represents >15% of Cortrophin use already, scope to grow further
→Q3 2026 SYNCHRONICITY Phase 4 trial NIU-PS readout — potential ILUVIEN re-rating
→M&A optionality: $311M cash + buyback flexibility, specialty BD pipeline
→Short-squeeze potential on Q2 2026 beat (15.8% SI)
→Prefilled-syringe Cortrophin launch (FDA-approved Mar 2025) — adherence + market expansion

Threats

!Cortrophin growth saturation as ACTH penetration matures
!US drug pricing reforms (IRA expansion, PBM reform) targeting specialty pharma
!ACTH biosimilar / competitive entry — niche segment, low probability but high impact
!Convertible note conversion if shares rally — dilution overhang
!Macro: rate environment + sector rotation away from specialty pharma

article

Summary by assessment area

🟢 Financial risk — Low

Net leverage 1.3x EBITDA, $311M cash cushion
FY26 OCF run-rate ~$220M+; FCF positive and growing
$100M buyback signals confident capital return posture

🟡 Business risk — Moderate

Cortrophin concentration (~50% revenue) is the key swing factor
Generics segment provides ballast but low growth/margin
ILUVIEN bull case capped by NEW DAY trial outcome

🔵 Valuation risk — Favorable

Forward P/E ~8.5x vs growth profile +20% revenue YoY
Base FV $105 → +31% upside; Bull $120-135 → +50% to +68%
Analyst consensus $113-115 corroborates re-rating thesis

2026-08-07 earnings

Q2 2026 Earnings Release (estimated)

short-term Impact: High Direction: Binary

First print after the raised FY26 guidance. Cortrophin run-rate confirmation, gout uptake datapoints, possible second guide raise. With 15.8% short interest, an in-line/beat print could trigger squeeze dynamics; a miss would compress the multiple toward peer median.

2026-07-15 operational

~90-person Rare Disease org expansion for gouty arthritis launch

short-term Impact: Medium Direction: Bullish

Cortrophin is the only FDA-approved ACTH for acute gouty arthritis. The 90-person sales force expansion deploys mid-2026 to capture this dedicated indication. Today gout already represents >15% of Cortrophin use; full sales coverage could double that share.

2026-09-30 capital_markets

$100M buyback execution pace (3-year program, May 2029 expiry)

medium-term Impact: Medium Direction: Bullish

Board-authorized May 8, 2026, $100M repurchase via open market, 10b5-1, and negotiated transactions. Run-rate ~$33M/year ≈ 1.8% of float annually. Provides downside support and signals management's confidence in cash generation.

2026-09-30 regulatory

SYNCHRONICITY Phase 4 trial in NIU-PS — Q3 2026 readout

medium-term Impact: High Direction: Binary

Phase 4 trial of ILUVIEN in non-infectious posterior uveitis (NIU-PS). Management has committed to medical-conference presentation in Q3 2026. Positive data could partially restore the ILUVIEN expansion narrative damaged by the NEW DAY primary endpoint miss in DME.

2026-11-06 earnings

Q3 2026 Earnings Release (estimated)

medium-term Impact: High Direction: Binary

First print fully reflecting gout-flare sales force deployment (mid-2026). Key metrics: Cortrophin Rx growth, gout share of mix, gross margin trajectory, FY27 preliminary guidance.

2026-12-31 regulatory

Cortrophin Phase 4 trial — acute gouty arthritis flares update

medium-term Impact: Medium Direction: Bullish

Trial conducted by Dr. Hyon Choi (Massachusetts General Hospital), comparing Cortrophin Gel head-to-head in acute gout. Even interim safety/efficacy readouts could solidify payer formulary positioning.

2027-01-15 guidance

FY27 Preliminary Guidance + J.P. Morgan Healthcare Conference

long-term Impact: High Direction: Bullish

Mid-January typically brings ANI's preliminary FY27 financial outlook plus JPM Healthcare presentation. Likely framing: Cortrophin sustained 20-30% growth, gout commercialization data, ILUVIEN trajectory post-SYNCHRONICITY, capital allocation update.

2026-12-31 ma

Potential bolt-on BD / M&A in specialty pharma

medium-term Impact: Medium Direction: Bullish

$311M cash, low net leverage, and Lalwani's commercialization track record support continued bolt-on appetite in specialty/rare disease. Management has highlighted strategic BD as a 2026 priority. Modest tactical use of cash (not transformational) is the base case.

{ "verdict_label": {"it": "Risk/Reward Favorevole", "en": "Favorable Risk/Reward"}, "verdict_text": {"it": "Specialty pharma profittevole con beat-and-raise Q1 2026 (+20.5% revenue, EPS raddoppiato), franchise Rare Disease in crescita 37%, buyback $100M, forward P/E ~8.5x sotto la mediana dei peer. Base FV $105 (+31% vs $80.34). Rischi: short interest 15.8%, debito $625M, concentrazione Cortrophin.", "en": "Profitable specialty pharma with Q1 2026 beat-and-raise (+20.5% revenue, EPS doubled), Rare Disease franchise growing 37%, $100M buyback, forward P/E ~8.5x below peer median. Base FV $105 (+31% vs $80.34). Risks: 15.8% short interest, $625M debt, Cortrophin concentration."}, "bull_points": [ {"it": "Cortrophin Gel +42% YoY, unica terapia ACTH approvata FDA, espansione gout in arrivo", "en": "Cortrophin Gel +42% YoY, only FDA-approved ACTH therapy, gout indication launch underway"}, {"it": "Guidance FY26 alzata a $1.08-1.14B + buyback $100M + cassa $311M", "en": "FY26 guidance raised to $1.08-1.14B + $100M buyback + $311M cash position"}, {"it": "Forward P/E ~8.5x vs peer median ~12x: spazio per re-rating su esecuzione", "en": "Forward P/E ~8.5x vs peer median ~12x: re-rating room on execution"} ], "bear_points": [ {"it": "Concentrazione Cortrophin ~50% del fatturato: vulnerabilità single-product", "en": "Cortrophin concentration ~50% of revenue: single-product vulnerability"}, {"it": "$625M debito incluso convertibili: dilution overhang strutturale", "en": "$625M debt including convertibles: structural dilution overhang"}, {"it": "NEW DAY trial: primary endpoint mancato, limita il caso bull per ILUVIEN", "en": "NEW DAY trial: primary endpoint missed, caps ILUVIEN bull case"} ], "risks": [ {"it": "Saturazione penetrazione ACTH se gout non ramp come previsto", "en": "ACTH penetration saturation if gout indication doesn't ramp as expected"}, {"it": "Pressione pricing US drug reform (IRA, PBM rebate)", "en": "US drug pricing reform pressure (IRA, PBM rebate compression)"}, {"it": "Short interest 15.8% binary: squeeze in beat, accelerazione downside in miss", "en": "Short interest 15.8% is binary: squeeze on beat, downside acceleration on miss"} ] }

Sources & Disclaimer

Sources: ANI Pharmaceuticals 8-K (May 8, 2026 Q1 earnings release), Form 10-Q Q1 2026, Globe Newswire press releases, Stock Analysis, Stocktitan, Yahoo Finance, Robinhood, Marketbeat, Insider Monkey, Zacks, GuruFocus. Market data — last verified close 2026-06-09: ANIP ~$80.34, market cap ~$1.78B, 52W: $56.71–$99.50, shares outstanding 22.75M. Short interest: 15.76% (3.58M shares). Cash $311.2M / Total debt $625M / Net leverage ~1.3x. Q1 2026 revenue $237.5M (+20.5% YoY), Cortrophin $75.1M (+42.1% YoY), ILUVIEN $19.3M (+19.5% YoY). FY26 guidance raised: revenue $1.08-1.14B, Cortrophin $540-575M, ILUVIEN $78-83M, adj EPS $9.19-9.69. Buyback $100M authorized May 8, 2026 through May 2029. Analyst consensus: median target $113, average $115, 7 Buy / 1 Hold / 0 Sell ratings (12 analysts, June 2026 update). This document is for informational purposes only and does not constitute financial or investment advice.